Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care
This webinar presents an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.
Michael Berger, Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, discusses the implementation of MSK-IMPACT, an NGS panel that analyzes both tumor and matched normal tissue to detect protein-coding mutations, copy number alterations, and certain promoter mutations and structural rearrangements in cancer-associated genes.
The panel, which currently covers 468 genes, has allowed a large number of patients to enroll in clinical trials of targeted treatments, according to a study published by Berger and colleagues earlier this year based on the results from sequencing around 10,000 patients. The MSKCC team found that around a third of these patients harbored actionable mutations and 11 percent of patients participated in a genomically matched clinical trial based on their results.
Since then, the MSKCC team has profiled a total of 20,000 patients with the panel. Dr. Berger discusses lessons learned from this implementation process, including:
- Considerations in assay design
- Challenges in large-scale implementation
- Integration with informatics systems
- Assessment of clinical utility
- Opportunities for clinical, translational, and basic research
Dr. Nevenka Dimitrova discusses how the Philips IntelliSpace Genomics platform addresses the challenges of implementing molecular profiling panels at healthcare systems with integrated clinical-genomic data, up-to-date variant interpretation and seamless workflow for precision oncology.